Hospital
RCHP Ottumwa LLC
RCHP Ottumwa LLC was paid $9.58M by Medicaid between Jan 2018 and Dec 2024, across 95 billing codes. Its largest line is 99284, emergency room visit (serious) — 30% of everything it billed.
33Billing provider infoRCHP OTTUMWA LLC
OTTUMWA, IA 52501
OTTUMWA, IA 52501
33aNPI1013233741assigned 04/20/2010
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.58M
24GClaims192,697
24DCodes billed95
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Iowa
Rank by total paid#13 of 29
Median peer was paid$6.37M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 32,027 | $1.84M | |
| 2019 | 29,042 | $1.46M | |
| 2020 | 27,885 | $1.24M | |
| 2021 | 32,969 | $1.54M | |
| 2022 | 36,702 | $1.70M | |
| 2023 | 23,563 | $1.15M | |
| 2024incomplete | 10,509 | $652K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 14,208 | 12,921 | $2.91M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 28% | 18,648 | 17,177 | $2.71M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 4,770 | 4,236 | $1.51M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.0% | 4,990 | 4,451 | $576K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 4.4% | 1,025 | 942 | $417K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 3.5% | 2,081 | 953 | $332K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.4% | 3,745 | 2,481 | $232K |
| 97597 | 1.5% | 1,851 | 935 | $144K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.5% | 3,672 | 3,251 | $141K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 2,111 | 1,935 | $136K |
| 71045 | Radiologic examination, chest; single view | 1.3% | 2,452 | 2,122 | $129K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,427 | 1,304 | $83K |
83 more codes
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 398 | $38K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,843 | $30K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 495 | $27K |
| 93458 | <1% | 15 | $25K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 163 | $21K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 25 | $20K |
| J3490 | Unclassified drugs | <1% | 5,593 | $15K |
| 29581 | <1% | 193 | $14K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 253 | $12K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 452 | $11K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,013 | $7K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 28 | $6K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 47 | $4K |
| 62323 | <1% | 14 | $4K | |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 412 | $4K |
| 59025 | Fetal non-stress test | <1% | 22 | $3K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,434 | $2K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 37 | $2K |
| A0425 | Ground mileage, per statute mile | <1% | 1,297 | $2K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 77 | $2K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 32 | $1K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 13 | $1K |
| 80053 | Comprehensive metabolic panel | <1% | 20,915 | $1K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 22,611 | $1K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 138 | $695.63 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 12 | $609.46 |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,448 | $597.18 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,356 | $386.26 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,054 | $303.23 |
| 84484 | <1% | 6,073 | $275.67 | |
| 87999 | <1% | 2,001 | $251.00 | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,662 | $177.69 |
| 83690 | <1% | 1,896 | $154.75 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,381 | $154.09 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 340 | $153.93 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 66 | $92.00 |
| 81001 | <1% | 5,427 | $52.34 | |
| 87070 | <1% | 297 | $35.58 | |
| 86140 | <1% | 2,504 | $26.82 | |
| 81025 | <1% | 933 | $25.02 | |
| 81003 | <1% | 2,141 | $19.23 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,850 | $15.68 |
| 80305 | <1% | 594 | $12.21 | |
| 87807 | <1% | 28 | $11.79 | |
| 85610 | <1% | 830 | $9.09 | |
| 87088 | <1% | 366 | $8.81 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,950 | $8.78 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,332 | $8.37 |
| 85730 | <1% | 278 | $7.40 | |
| 83880 | <1% | 222 | $6.57 | |
| 88304 | <1% | 100 | $3.01 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,099 | $1.93 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 861 | $1.86 |
| 85027 | <1% | 22 | $0.96 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,310 | $0.55 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,078 | $0.36 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 968 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 583 | $0.00 |
| C1769 | Guide wire | 0% | 14 | $0.00 |
| 83735 | 0% | 746 | $0.00 | |
| 82077 | 0% | 979 | $0.00 | |
| G0378 | Hospital observation service, per hour | 0% | 118 | $0.00 |
| 83605 | 0% | 729 | $0.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 755 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 35 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 31 | $0.00 |
| 87040 | 0% | 177 | $0.00 | |
| 87081 | 0% | 66 | $0.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 95 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 33 | $0.00 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 0% | 58 | $0.00 |
| 85379 | 0% | 103 | $0.00 | |
| 84703 | 0% | 62 | $0.00 | |
| 82803 | 0% | 13 | $0.00 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 16 | $0.00 |
| 87077 | 0% | 27 | $0.00 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 0% | 695 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 84 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 77 | $0.00 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 91 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 74 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 42 | $0.00 |
| Q9960 | High osmolar contrast material, 200-249 mg/ml iodine concentration, per ml | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.